Update shared on10 Aug 2025
Fair value Decreased 23%Health Catalyst’s consensus price target has been reduced to $5.78, primarily reflecting a deterioration in net profit margin despite a lower discount rate.
What's in the News
- CEO Dan Burton will step down effective June 2026, transitioning from his full-time role while continuing to assist the Board and serve as a director.
- The company reported a $28.8 million goodwill impairment charge for Q2 2025.
- Earnings guidance projects Q3 2025 revenue of ~$75 million and full-year 2025 revenue of ~$310 million.
- Health Catalyst launched 10 AI-integrated healthcare data toolkits on the Databricks Marketplace, advancing partnerships and expanding its analytics offerings.
- The company has been dropped from multiple Russell growth and small-cap indices, including Russell 2000, 2500, 3000, and Microcap Growth benchmarks.
Valuation Changes
Summary of Valuation Changes for Health Catalyst
- The Consensus Analyst Price Target has significantly fallen from $6.89 to $5.78.
- The Net Profit Margin for Health Catalyst has significantly fallen from 11.52% to 8.59%.
- The Discount Rate for Health Catalyst has significantly fallen from 11.56% to 9.99%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.